Supply Chain Intelligence

Taysha Gene Therapies, Inc. Supply Chain

TSHA supply chain intelligence for Taysha Gene Therapies, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

TSHA ·Last updated 2026-07-30 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

8Suppliers
2Customers
3Debt Items
14Related Chains

Taysha Gene Therapies, Inc. Suppliers

TickerNameConfidenceEvidence
ASTELLAS ASTELLAS 90% As further consideration for the rights granted to Astellas under the Option Agreement, the Company and Astellas also entered into the Astellas Securities Purchase Agreement
AUDENTES-THERAPEUTICS-INC-D-B-A-ASTELLAS-GENE-TH AUDENTES-THERAPEUTICS-INC-D-B-A-ASTELLAS-GENE-TH 90% the option agreement dated October 21, 2022, or the Option Agreement, with Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy), or Astellas
THE-UNIVERSITY-OF-TEXAS-SOUTHWESTERN-MEDICAL-CEN THE-UNIVERSITY-OF-TEXAS-SOUTHWESTERN-MEDICAL-CEN 90% In connection with the UT Southwestern Agreement, we obtained an exclusive, worldwide, royalty-free license under certain patent rights of UT Southwestern
SSI SSI 85% SSI provides certain consulting services to the Company
ABEONA-THERAPEUTICS-INC ABEONA-THERAPEUTICS-INC 80% pursuant to which we obtained an exclusive, worldwide, royalty-bearing license, with the right to grant sublicenses under certain patents, know-how and materials originally developed by the Universit…
SILICON-VALLEY-BANK SILICON-VALLEY-BANK 80% from our previous loan agreement with Silicon Valley Bank
TRINITY-CAPITAL TRINITY-CAPITAL 80% from our current loan agreement with Trinity Capital
RGNX REGENXBIO Inc. 72% Reciprocal relationship from RGNX graph: atent that will expire in 2034, one issued U.S. patent that will expire in 2038, one issued U.S. patent that will expire in 2039, one issued U.S. patent that …

Taysha Gene Therapies, Inc. Customers

TickerNameConfidenceEvidence
RGNX REGENXBIO Inc. 72% Reciprocal relationship from RGNX graph: atent that will expire in 2034, one issued U.S. patent that will expire in 2038, one issued U.S. patent that will expire in 2039, one issued U.S. patent that …
EMERGING-GROWTH-COMPANY EMERGING-GROWTH-COMPANY 62% . The Trinity Term Loans contains various embedded features and the election of the fair value option allows us to bypass analysis of potential embedded derivatives and further analysis of bifurcatio…

Taysha Gene Therapies, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
TSHA-DEBT-13123 Xbrl Convertible 90% xbrl convertible detail from xbrl 2020-12-31.
TSHA-DEBT-13122 Warrants outstanding: 1637000 90% xbrl warrant detail from xbrl 2025-12-31.
TSHA-DEBT Debt stack $68.6M 90% Market cache reports total debt of $68.6M.

Taysha Gene Therapies, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Taysha Gene Therapies, Inc..

Taysha Gene Therapies, Inc. Ownership

HolderNameConfidenceEvidence
TSHA-OWNER-MORGAN-STANLEY MORGAN STANLEY 90% 13F overlay lists MORGAN STANLEY as top holder; 195 tracked holders.

Taysha Gene Therapies, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
SI Shoulder Innovations, Inc. 100.00 2
CADL Candel Therapeutics, Inc. 100.00 2
RPID Rapid Micro Biosystems, Inc. 100.00 2
RGNX REGENXBIO Inc. 100.00 1 ['customer', 'supplier']
DNLI Denali Therapeutics Inc. 50.00 2
TNYA Tenaya Therapeutics, Inc. 50.00 2
SRPT Sarepta Therapeutics, Inc. 50.00 2
NVSEF Novartis AG 50.00 2
REGN Regeneron Pharmaceuticals, Inc. 50.00 2
FDMT 4D Molecular Therapeutics, Inc. 50.00 2
OTLK Outlook Therapeutics, Inc. 50.00 2
CORZ Core Scientific, Inc. 50.00 2
RARE Ultragenyx Pharmaceutical Inc. 50.00 2
TRIN Trinity Capital Inc. 38.88 1 ['receiving']
View TSHA supply chain intel →

Explore the full interactive supply chain map for Taysha Gene Therapies, Inc..

Open TSHA supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map